Background: The use of tissue plasminogen activator (tPA) for the treatment of frostbite has been reported and advocated, but its efficacy has not been well established. We conducted a systematic review to guide physicians on the role of tPA in the treatment of frostbite. Our hypothesis was that the use of tPA improves clinical outcomes, as measured by amputation rate. Methods: We searched MEDLINE (PubMed) and EMBASE for primary research articles on the use of tPA for the treatment of extremity frostbite. Information related to study design, outcomes, and complications was extracted. A total of 204 citations were screened, and then 35 abstracts and 24 reports were reviewed. Fifteen studies met the standard for final review. Results: One randomized, prospective study; 3 cohort studies; 8 case series; and 3 case reports were found. A total of 208 patients were treated. Differences in protocols, inclusion criteria, and outcomes measures prevented combining the study results. In all the studies, the authors reported that the use of tPA was or may have been useful in reducing amputation rates or increasing tissue salvage. Complication rates ranged from 0% to 100%, with a combined rate of 13%. The quality of the evidence was low. Conclusions: Due to the low scientific quality of the studies, the efficacy of tPA in reducing amputation rates cannot currently be established. Randomized, prospective trials or well-controlled cohort studies are needed to better assess the role of tPA. Consideration should be given to limiting its use to research protocols.
Introduction
Frostbite is damage caused by the freezing of tissue. In civilian populations, it is often seen in the presence of cognitive impairment due to alcohol, drugs, or psychiatric conditions. People working outside in extreme cold, those injured in vehicular accidents, and extreme sports enthusiasts including mountain climbers are also prone to frostbite. [1] [2] [3] It is a persistent problem in military populations. 4 The severity can range from superficial whitish plaques with surrounding mild erythema (first degree), to clear blisters (second degree) or hemorrhagic blisters (third degree), up to hard, mottled, insensate tissue (fourth degree). Two mechanisms, direct cellular damage and progressive dermal ischemia, lead to the tissue damage seen in frostbite. The progressive dermal ischemia is similar to reperfusion injury. The release of inflammatory mediators leads to edema formation and endothelial injury. Dermal blood flow is then stopped by microemboli. 5, 6 The diagnosis of frostbite is primarily made on clinical examination. Imaging with arteriography and bone scan is often used to assess perfusion. Treatment for many decades has centered on rapid rewarming followed by optimal wound care. [7] [8] [9] Surgery is typically delayed for weeks until gangrenous tissue has clearly demarcated. [8] [9] [10] [11] Numerous studies have reported on the use of other medications and adjunctive therapies, such as heparin, Dextran, reserpine, hyperbaric oxygen, and sympathectomy. No proven clinical value has been shown. 7, 9, 12, 13 Iloprost, a prostacycline that has vasodilatory, fibrolysis enhancing, and anti-platelet activity, has also been used with limited reports of benefits in preserving damaged tissue. 1, [14] [15] [16] [17] [18] Currently, iloprost is not available in an injectable form in the United States. The use of tissue plasminogen activator (tPA) in the treatment of frostbite has been reported since 1992, but the efficacy of this treatment has not been well established. 19 The rationale behind using tPA for treatment is based on the potential of tPA to lyse microvascular thrombus and emboli. The use of tPA for the treatment of frostbite is an off-label use that is not approved by the U.S. Food & Drug Administration.
The purpose of this study was to conduct a systematic review to evaluate the role of tPA in the treatment of frostbite. Our hypothesis was that the use of tPA improves clinical outcomes as measured by digit amputation rate.
Materials and Methods

Eligibility
Primary research articles that reported on the use of tPA for the treatment of extremity frostbite were included in our review. The inclusion criteria allowed prospective and retrospective studies, including case series and case reports. Case series and case reports were included due to the limited amount of research that has been done on the topic. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.
Strategy
We searched MEDLINE (PubMed) and EMBASE from the inception of the database to December 9, 2017. The search terms were "frostbite" linked with "tissue plasminogen activator OR tPA OR amputation OR anti-platelet therapy OR extremity salvage." The search was confined to studies published in English. The 2 authors independently screened the articles by title and then by the contents of the abstracts for inclusion. The other author was available to mediate conflicts. All authors reviewed the final article. The results of a study that were only reported in a Letter to the Editor were included since this study was the only randomized, controlled study found in the search.
Data Extraction
Data extracted from the studies included author(s), journal, year of publication, level of evidence, treatment group size, control group size, criteria for treatment, complications, route of tPA administration, diagnostic studies, outcome measures, outcomes, complications, and use of additional medications. The reviewers used a data collection spreadsheet to collect data.
Assessment of Quality
All the articles were assessed using the Oxford Centre for Evidence-based Medicine -Levels of Evidence (March  2009) . 20 The quality of the randomized control study was assessed using the Cochrane risk of bias tool. 21 The cohort studies were scored on the Newcastle-Ottawa scale.
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Results
The initial search identified 204 potential articles ( Figure 1 ). After reviewing the titles, the abstracts for 35 articles were reviewed. Of the 24 articles read, 15 were included in the final analysis. One excluded article studied patients who were later reported in a subsequent publication. The other excluded articles did not specifically report results of treatment of frostbite with tPA.
A total of 208 patients were included in the treatment groups. Only 1 randomized, prospective study was found (16 treated patients, 31 controls). 23 Three studies included a control group (59 treated patients, 73 controls). [24] [25] [26] None of the control groups were well matched. The 8 case series reported on 128 patients. 17, [27] [28] [29] [30] [31] [32] [33] Three studies were case reports. [34] [35] [36] A total of 208 patients were included in the treatment groups. In all the studies, the authors reported that the use of tPA was or may have been useful based on reducing amputation rates or increasing tissue salvage. Table 1 summarizes the reports. Differences in study design, inclusion criteria, treatment protocols, use of anticoagulation and other adjuvant therapies, and outcomes measures prevented combining the study results. There was no uniformity in inclusion criteria or outcome measures. Inclusion criteria included the clinical diagnosis of severe frostbite, with some articles using angiography, triple-phase bone scan, or both for diagnosis. The tPA was given either by the intra-arterial or intravenous route. Successful outcomes criteria in the studies included amputation rate of digits and/or the number of patients requiring amputation (10), change in pretreatment prediction of outcome (1), response to treatment on angiogram (3), and response to treatment on bone scan (1). Complication rates ranged from 0% to 100%. Overall combined complication rate was 13%.
Complications included bleeding at the catheter sites, femoral pseudoaneurysm, and a retroperitoneal hematoma. Complication rates were the same for protocols administering tPA intravenously compared with intra-arterially. There were no deaths reported. Two studies did not report if there were any complications. All the protocols required the care and monitoring of the patient treated with tPA to be performed in an intensive care unit (ICU) setting.
There was one level 2b (low quality randomized control study), 3 level 3b (individual case-control studies), and 11 level 4 studies (case series or report). Cochrane risk of bias scores for the prospective study was unclear risk. There was not enough information provided to judge whether the study had "low" or "high" risk of bias (Table 2) . 21 The Newcastle-Ottawa scores for the cohort studies were 6 out of 9 (Table 3) .
Discussion
Due to the low level of the scientific evidence produced by these studies, the hypothesis cannot currently be supported. All but one of the 15 studies reviewed provided level 3b or 4 evidence based on the Oxford Centre criteria. The 3 cohort studies were categorized as level 3b due to the lack of wellmatched control groups. 20 Cauchy et al presented a randomized, controlled study that included the use tPA for the treatment of frostbite. 23 The reporting of the study was substandard due to the results being published as a Letter to the Editor. The risk of bias could not be adequately assessed (Table 2) . We included this study in our review, as it was the only level 2 study that we found. Unfortunately, the protocol did not administer tPA alone. Instead, it was given along with iloprost. Patients treated with iloprost alone had the lowest amputation rate (0%), followed by the iloprost plus tPA group (3%) and the buflomedil control group (39%). They concluded that all frostbite patients should be treated with iloprost, and the use of tPA should be decided on a case-by-case basis.
Three studies were reported as cohort studies, but all 3 failed to adequately match the control groups to the tPA groups. Nygaard et al found differences in the patients treated with tPA compared with a control group, but the overall difference was not statistically significant. 25 There was no uniformity in inclusion criteria in the articles. Criteria included clinical assessment alone, or clinical assessment plus angiography and/or Tc-99m bone scan. None of these approaches, when performed soon after injury, has been shown to predict prognosis. Clinical examination is notably unreliable. 7 Bone scan performed before the third post-injury day has not been shown to be able to predict digit loss. 37 The prognostic value of perfusion defects demonstrated with angiography is unclear. 38 Given the difficulty in using imaging studies to assess prognosis early in the course of frostbite, it is difficult to judge the value of treatment modalities when allocation to treatment is dependent on the imaging studies.
Complication rates varied, with equal rates reported for the intra-arterial and intravenous route of administration. In one study, administration of tPA was switched from intraarterial to intravenous due to unreported benefits to limbs that were untreated with intra-arterial administration. 32 The other studies did not explain the rationale behind their choice of administration. The differences in the cost of treatment between the treatment and control groups were not presented.
Limitations of our study include the use of only 2 databases and restricting the review to studies published in Englishlanguage journals. The absence of uniform eligibility criteria, outcome measures, treatment methods, and reporting prevented us from combining the results of the studies.
Based on the reviewed literature, there is limited highlevel evidence supporting use of tPA for the treatment of frostbite. Treatment with tPA presumably increases costs due to the need for advanced imaging, the medication, and the need for care in the ICU. Before the use of tPA becomes widespread or standardized in treatment protocols, better studies, including randomized, prospective studies, need to be performed. These studies will be difficult to design, as it is difficult to assign the risk of amputation prior to early treatment. If the efficacy of tPA is to be demonstrated, further studies need to define which degree of frostbite should be treated; the proper starting point, end point, and duration of treatment; the preferred route of administration; and the cost. The potential benefit of early treatment needs to be assessed. In addition, the effects of anticoagulation and other associated adjuvant medications and treatments will need to be analyzed. Treatment with tPA also needs to be rigorously compared to treatment with iloprost. Consideration should be given to limiting its use to research protocols. 
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